John Garvey, socio de Foley Private Equity & Venture Capital, moderó esta sesión con los ponentes Josh Hamermesh, de Molecular Insight Pharmaceuticals, Inc., y Matt Karlyn, de Foley. Abordaron el tema de la licencia de tecnología, concretamente cómo identificar posibles oportunidades de beneficio; cómo acercarse a posibles socios comerciales, la diligencia debida previa a la transacción; la negociación con el licenciante; y la integración de la tecnología licenciada en las operaciones comerciales de la empresa.
Información relacionada
December 24, 2025
Health Care Law Today
Gender-Affirming Care: Multi‑State Lawsuit Challenges HHS Declaration
As previously discussed in Foley’s healthcarelawtoday, on December 18, 2025, the U.S. Department of Health & Human Services (HHS) held a press conference focused on what it defined as “sex rejection procedures” (SRPs), also known as gender-affirming care (GAC) for minors, and outlined next steps.
December 23, 2025
Energy Current
FERC Opens New Paths for Co-Located Loads in PJM: What Data Center and Power Generation Developers Need to Know
Key Takeaways FERC has ordered PJM to overhaul its tariff framework for co-located generation and large loads, finding existing rules…
Diciembre 23, 2025
Puntos de vista de Foley
The Rush to Exit: PE Firms Pick Up the Pace in 2025
Key Points: PE firms are moving to sell portfolio companies on an accelerated timeline in 2025 after years of much longer hold…